02269

40.9606.57%
XG

Xuejun Gu

CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director

Dr. Xuejun Gu, also known as Sherry, Ph.D., serves as Chief Technology Officer, Executive Vice President of Global Biologics Development Department of WuXi Biologics (Cayman) Inc. since March 31, 2024 and serves as its Chief Client Officer since 2026 and serves as Executive Director since June 6, 2025. She joined Company in 2017 as the Vice President of CMC (Chemistry, Manufacturing and Controls) Management for the West Coast of the United States and expanded her responsibilities to include the East Coast of the United States in 2019 and Europe in 2021. During such period, she led numerous early and late-stage CMC projects directly and achieved several project IND (Investigational New Drug), PPQ (Process Performance Qualification) and approval milestones, including from DNA to EUA (Emergency Use Authorization) approval of Sotrovimab through the VIR-GSK collaboration in the combat of the worldwide COVID-19 pandemic. Dr. Gu received her Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology and has been working in the biopharmaceutical field for many years, including 2 years at Bristol Myers Squibb and many years at Eli Lilly and Company prior to joining the Company.

Positions